A BILL FOR AN ACT

RELATING TO MEDICAL CANNABIS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECT	ION 1. The legislature finds that amendments to					
2	chapter 3	29D, Hawaii Revised Statutes, are warranted to clarify					
3	legislati	ve intent, ensure smooth administration of the law,					
4	allow for	adequate patient access based on experiences in other					
5	states that have a reasonable medical cannabis program, and						
6	resolve o	ther issues that have arisen under the existing law.					
7	The	purposes of this Act are to:					
8	(1)	Allow for a process to remediate any batch of cannabis					
9		that fails laboratory testing standards so long as any					
10		final product passes all such laboratory standards;					
11	(2)	Authorize licensed retail dispensaries to sell edible					
12		cannabis products under certain conditions; and					
13	(3)	Authorize licensed dispensaries to circulate, sponsor,					
14		and promote educational and scientific information and					
15		events related to cannabis.					



H.B. NO. 2097

SECTION 2. Section 329D-1, Hawaii Revised Statutes, is
 amended by amending the definition of "manufactured cannabis
 products" to read as follows:

""Manufactured cannabis product" means any capsule,
lozenge, oil or oil extract, tincture, ointment or skin lotion,
pill, transdermal patch, or pre-filled and sealed container used
to aerosolize and deliver cannabis orally, such as an inhaler or
nebulizer, that has been manufactured using cannabis, or any
other products as specified by the department pursuant to
section [329D-10(a)(10).] 329D-10(a)(11)."

SECTION 3. Section 329D-8, Hawaii Revised Statutes, is amended by amending subsection (a) to read as follows:

13 "(a) The department shall establish and enforce standards 14 for laboratory-based testing of cannabis and manufactured 15 cannabis products for content, contamination, and consistency; 16 provided that in establishing these standards, the department 17 shall:

18	(1)	Review	and	take	guidan	ce fr	om t	he	testing	programs	and
19		standar	ds ı	ıtiliz	zed in	other	jur	risd	lictions;	;	

20 (2) Consider the impact of the standards on the retail21 cost of the product to the qualifying patient;



Page 2

H.B. NO. 2097

	<i>i</i> -	
1	(3)	Review and take guidance from the testing programs and
2		standards for pesticides under the regulations of the
3		United States Environmental Protection Agency;
4	(4)	Consider processes that allow any batch of product
5		that fails testing standards to be remediated and
6		manufactured so long as any final product passes
7		testing standards;
8	[-(4) -]	(5) For the testing for microbiological impurities,
9		consider the benefits of organically grown cannabis
10		that features the use of bacteria in lieu of
11		pesticides; and
12	[(5)]	(6) Include permission for qualifying patients and
13		primary caregivers to obtain testing services directly
14		from certified laboratories on the island where the
15		qualifying patient and primary caregiver reside."
16	SECT	ION 4. Section 329D-10, Hawaii Revised Statutes, is
17	amended to	o read as follows:
18	"§32	9D-10 Types of manufactured cannabis products. (a)
19	The types	of medical cannabis products that may be manufactured
20	and distr	ibuted pursuant to this chapter shall be limited to:
21	(1)	Capsules;

2020-0517 HB SMA.doc

H.B. NO. 2097

- 1 (2) Lozenges;
- 2 (3) Pills;
- 3 (4) Oils and oil extracts;
- 4 (5) Tinctures;
- 5 (6) Ointments and skin lotions;
- **6** (7) Transdermal patches;
- 7 (8) Pre-filled and sealed containers used to aerosolize 8 and deliver cannabis orally, such as with an inhaler 9 or nebulizer; provided that containers need not be 10 manufactured by the licensed dispensary but shall be 11 filled with cannabis, cannabis oils, or cannabis 12 extracts manufactured by the licensed dispensary; 13 shall not contain nicotine, tobacco-related products, 14 or any other non-cannabis derived products; and shall 15 be designed to be used with devices used to provide 16 safe pulmonary administration of manufactured cannabis 17 products;
- 18 (9) Devices that provide safe pulmonary administration;19 provided that:



1		(A)	The heating element of the device, if any, is
2			made of inert materials such as glass, ceramic,
3			or stainless steel, and not of plastic or rubber;
4		(B)	The device is distributed solely for use with
5			single-use, pre-filled, tamper-resistant, sealed
6			containers that do not contain nicotine or other
7			tobacco products;
8		(C)	The device is used to aerosolize and deliver
9			cannabis by inhalation, such as an inhaler,
10			medical-grade nebulizer, or other similar medical
11			grade volitization device;
12		(D)	There is a temperature control on the device that
13			is regulated to prevent the combustion of
14			cannabis oil; and
15		(E)	The device need not be manufactured by the
16			licensed dispensary; [and]
17	(10)	Edib	le cannabis products; and
18	[(10)]	(11)	Other products as specified by the department.
19	(b)	As u	sed in this section, "lozenge" means a small
20	tablet man	nufac	tured in a manner to allow for the dissolving of
21	its medic	inal	or therapeutic component slowly in the mouth.

2020-0517 HB SMA.doc

1	(C)	As u	sed in this section, "edible cannabis products"
2	means pro	ducts	intended for human consumption that are infused
3	with any	canna	binoid extracted from the cannabis plant, as
4	regulated	by a	dministrative rules of the department; provided
5	that thes	e pro	ducts shall:
6	(1)	Unde	rgo and pass laboratory testing as required under
7		sect	ion 329D-8;
8	(2)	Meet	all requirements under section 329D-11,
9		incl	uding:
10		(A)	Providing the following in no less than ten-point
11			font: "WARNING: CONTAINS CANNABIS AND IS FOR
12			MEDICAL USE. THIS IS NOT FOOD. KEEP OUT OF
13			REACH OF CHILDREN";
14		<u>(B)</u>	Providing a list of all ingredients;
15		(C)	Providing a statement that this product has
16			passed testing requirements; and
17		(D)	Ensuring that the words "candy" or "candies" or
18			"gummy" or "gummies" do not appear on the product
19			packaging; and
20	(3)	<u>Be</u> r	egulated and approved by the department as medical
21		manu	factured cannabis products and not under section





H.B. NO. 2097

1		328-1 as "food" and exempted from those further
2		requirements; provided that the product meets the
3		other requirements for manufactured products under
4		section 329D-9."
5	SECTI	ION 5. Section 329D-11, Hawaii Revised Statutes, is
6	amended to	o read as follows:
7	"§329	D-11 Advertising and packaging. (a) The department
8	shall esta	ablish standards regarding the advertising and
9	packaging	of cannabis and manufactured cannabis products;
10	provided t	that the standards, at a minimum, shall require the use
11	of packag:	ing that:
12	(1)	Is child-resistant and opaque so that the product
13		cannot be seen from outside the packaging;
14	(2)	Uses only black lettering on a white background with
15		no pictures or graphics;
16	(3)	Is clearly labeled with the phrase "For medical use
17		only";
18	(4)	Is clearly labeled with the phrase "Not for resale or
19		transfer to another person";
20	(5)	Includes instructions for use and "use by date";

2020-0517 HB SMA.doc

1	(6)	Contains information about the contents and potency of
2		the product;
3	(7)	Includes the name of the production center where
4		cannabis in the product was produced, including the
5		batch number and date of packaging;
6	(8)	Includes a barcode generated by tracking software; and
7	(9)	In the case of a manufactured cannabis product,
8		includes a:
9		(A) Listing of the equivalent physical weight of the
10		cannabis used to manufacture the amount of the
11		product that is within the packaging, pursuant to
12		<pre>section 329D-9(c);</pre>
13		(B) Clearly labeled warning stating that the product:
14		(i) Is a medication that contains cannabis, and
15		is not a food; and
16		(ii) Should be kept away from children; and
17		(C) Date of manufacture.
18	(b)	Any capsule, lozenge, or pill containing cannabis or
19	its princ	ipal psychoactive constituent tetrahydrocannabinol
20	shall be	packaged so that one dose, serving, or single wrapped
21	item cont	ains no more than ten milligrams of

H.B. NO. 2097

1 tetrahydrocannabinol; provided that no manufactured cannabis 2 product that is sold in a pack of multiple doses, servings, or 3 single wrapped items, nor any containers of oils, shall contain more than a total of one thousand milligrams of 4 5 tetrahydrocannabinol per pack or container; provided further 6 that no dispensary shall exceed the dispensing limits imposed by 7 section 329D-7. 8 All manufactured cannabis products shall be (C) 9 individually wrapped at the original point of manufacture. 10 (d) A dispensary shall be allowed to provide, disseminate, 11 and publish educational and scientific materials related to 12 cannabis and its products, and sponsor events about cannabis 13 that shall not be considered advertising so long as the purpose does not seek to promote only the interests of that dispensary." 14 SECTION 6. Statutory material to be repealed is bracketed 15 16 and stricken. New statutory material is underscored. 17 This Act shall take effect on July 1, 2020. SECTION 7. 18



2020-0517 HB SMA.doc

INTRODUCED BY: John M. Marine Ricken Sicken

Page 9

H.B. NO. 2097

Madrie K. Mah

JAN 1 7 2020



Report Title:

Medical Cannabis; Retail Dispensaries; Testing Standards; Edible Products; Educational and Scientific Information

Description:

Allows for a process to remediate any batch of cannabis that fails laboratory testing standards so long as any final product passes all such laboratory standards. Authorizes licensed retail dispensaries to sell edible cannabis products, under certain conditions, and circulate, sponsor, and promote educational and scientific information and events related to cannabis.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

